Table 1_Hematologic follow-up of metamizole-associated Heinz body anemia in dogs.docx

Metamizole is described as a potential trigger in isolated cases.</p>Aim of the study<p>The present study describes the course of metamizole-associated HB anemia in dogs with the development of hematocrit, HBs, and eccentrocytes. In addition, the correlation between HBs, eccentrocytes, hematocrit, and reticulocytes is investigated.</p>Materials and methods<p>In this prospective observational study, 25 dogs with metamizole-associated HB anemia were included.

Hematologic examinations and blood smear evaluations for quantification of HBs and eccentrocytes (stained with brilliant cresyl blue and modified Wright's stain) were performed on day 0 and at the control intervals 1–3, 4–6, 7–13, and 14–20 days after discontinuation of metamizole and initiation of antioxidant treatment. Known alternative causes of oxidative erythrocyte damage were excluded. Data were analyzed using Kruskal-Wallis test, Friedman test, and Spearman correlation.</p>Results<p>HB anemia was detected a median of 10 days after initiation of metamizole (median cumulative dose 720 mg/kg).